Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 8:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,005 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional

Adaptive Pet Study

NCT01908504
Conditions
Head and Neck Cancers, Lung and Esophagus Cancers, Anal, Cervix, Vulvar, Vaginal, and Endometrium Cancers
Interventions
PET-CT
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 100 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Recurrent Prostate Carcinoma
Interventions
Best Practice, Computed Tomography, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography
Other · Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Autologous Anti-CD83 CAR T-cells, Biospecimen Collection, Chest Radiography, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine Phosphate, Hydroxyurea, Leukapheresis, Lumbar Puncture, Positron Emission Tomography, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Glioma
Interventions
Fluorine F 18 Fluorodopa, Intensity-Modulated Radiation Therapy, Positron Emission Tomography
Drug · Radiation · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Thyroid Gland Carcinoma
Interventions
Gallium Ga 68-labeled PSMA-11, Magnetic Resonance Imaging, Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Francisco, California
Conditions
Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Renal Pelvis and Ureter Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v7, Stage IV Renal Pelvis and Ureter Cancer AJCC v7
Interventions
Best Practice, Biospecimen Collection, Central Venous Cannula Insertion, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Pembrolizumab, Plasmapheresis, Positron Emission Tomography, Questionnaire Administration, Antibody-Drug Conjugate Therapy
Other · Procedure · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Renal Tumor, Renal Cell Carcinoma, Renal Tumor, Benign
Interventions
2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Dallas, Texas • Houston, Texas
Conditions
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma, Refractory Hypopharyngeal Squamous Cell Carcinoma, Refractory Laryngeal Squamous Cell Carcinoma, Refractory Oral Cavity Squamous Cell Carcinoma, Refractory Oropharyngeal Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Biospecimen Collection, Cetuximab, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
200
States / cities
Little Rock, Arkansas • Marysville, California • Palo Alto, California + 161 more
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Carfilzomib, Dexamethasone, Pomalidomide, Quality-of-Life Assessment, Questionnaire Administration, Selinexor, X-Ray Imaging, Computed Tomography, Positron Emission Tomography, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection
Drug · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Glioblastoma, IDH-Wildtype
Interventions
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Fluciclovine F18, Gadolinium-Chelate, Magnetic Resonance Spectroscopy, Positron Emission Tomography
Procedure · Other · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 14 more
Conditions
Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Lung Cancer
Interventions
carboplatin, cisplatin, docetaxel, etoposide, paclitaxel, vinblastine sulfate, vinorelbine tartrate, gene expression analysis, positron emission tomography, fludeoxyglucose F 18, radiation therapy
Drug · Genetic · Procedure + 1 more
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
46
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 38 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects

NCT01265394
Conditions
Healthy
Interventions
[18F] Flutemetamol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years to 40 Years
Enrollment
218 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Desmoplastic Melanoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Elastography, Pembrolizumab, Positron Emission Tomography, Therapeutic Conventional Surgery
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
280
States / cities
Fairbanks, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 199 more
Conditions
Prostate Cancer
Interventions
PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 90 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
Interventions
Pirtobrutinib, Mosunetuzumab, Biospecimen Collection, Biopsy Procedure, Computed Tomography, Positron Emission Tomography, Bone Marrow Aspiration, Bone Marrow Biopsy, Questionnaire Administration
Drug · Biological · Procedure + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Bladder Cancer
Interventions
FDG PET/MR
Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Healthy Subject, Intracranial Neoplasm, Glioblastoma
Interventions
Fluorine F 18 DASA-23, Positron Emission Tomography
Drug · Procedure
Lead sponsor
Guido A. Davidzon, MD, SM
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Melanoma
Interventions
Anakinra, Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Tocilizumab
Biological · Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Leukemia, Multiple Myeloma
Interventions
Rituximab, Conditioning chemotherapy, TMS, FLAG, EPOCH-F, Hematopoietic stem cell transplant, Palifermin, Acetaminophen, Diphenhydramine, Prednisone, Epinephrine, IV Saline, ECG, ECHO, MUGA, DEXA, CT chest, PET, MRI, BM aspirate, BM biopsy, Lumbar puncture
Biological · Drug · Procedure + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland • Minneapolis, Minnesota
Conditions
Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Navitoclax, Positron Emission Tomography, Trametinib
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Zirconium Zr 89 Girentuximab
Procedure · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Cardiac Sarcoidosis
Interventions
hybrid PET/MRI
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Terminated No phase listed Observational Accepts healthy volunteers

Kappa Opioid Receptor Imaging in Anorexia

NCT02240797
Conditions
Anorexia Nervosa
Interventions
Positron emission tomography (PET) imaging
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York